Cambrex Corp (CBM) 48.07 $CBM Cambrex Reports Second

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cambrex Corp (CBM) 48.07 $CBM

Cambrex Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 6:00AM CDT
- Sales increased 12% for the quarter and full year sales and profit guidance increased -
CBM: 48.07 (-0.42)

Shares of CBM Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 21, 1:16AM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 31.81% as of today's recent price of $49.14.
CBM: 48.07 (-0.42)

Answerthink Announces "Go Live" at Cambrex Corporation On SAP(R) ERP and LabWare LIMS 6.0 Integration Through Integrated Web Services
BusinessWire - Tue Jun 07, 8:30AM CDT
Answerthink, a division of The Hackett Group, Inc.. (NASDAQ: HCKT) and a premier developer, provider and supporter of solutions based on SAP(R) software, today announced the successful implementation of a laboratory information management system (LIMS) solution at Cambrex Corporation's Sweden facility.
CBM: 48.07 (-0.42), HCKT: 14.04 (+0.30)

Cambrex Has Returned 35.9% Since SmarTrend Recommendation (CBM)
Comtex SmarTrend(R) - Fri Jun 03, 1:09PM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 4 months, Cambrex has returned 35.94% as of today's recent price of $50.68.
CBM: 48.07 (-0.42)

Cambrex to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Fri Jun 03, 10:00AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex" is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on June 10, 2016 at 10:00 a.m. EDT in New York City.
CBM: 48.07 (-0.42)

Cambrex Announces Closing of New $500 Million Senior Credit Facility
GlobeNewswire - Mon May 23, 5:45AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex" is pleased to announce that the Company has closed a new $500 million senior secured revolving credit facility (the "Credit Facility", replacing the previous $250 million facility.
CBM: 48.07 (-0.42)

Cambrex Up 25.2% Since SmarTrend Uptrend Call (CBM)
Comtex SmarTrend(R) - Thu May 19, 1:22PM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 3 months, Cambrex has returned 25.16% as of today's recent price of $46.66.
CBM: 48.07 (-0.42)

Cambrex to Present at UBS Global Healthcare Conference
GlobeNewswire - Mon May 16, 9:55AM CDT
Cambrex Corporation (NYSE:CBM) ("Cambrex" is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on May 23, 2016 at 9:30 a.m. EDT in New York City.
CBM: 48.07 (-0.42)

Cambrex Has Returned 26.8% Since SmarTrend Recommendation (CBM)
Comtex SmarTrend(R) - Thu May 12, 12:42AM CDT
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on February 10th, 2016 at $37.28. In approximately 3 months, Cambrex has returned 26.77% as of today's recent price of $47.26.
CBM: 48.07 (-0.42)

Kite Pharma (KITE) Posts Narrower-than-Expected Loss in Q1
Arpita Dutt - Zacks Investment Research - Tue May 10, 8:45AM CDT
Investors will remain focused on Kite's (KITE) progress with its pipeline.
HSKA: 46.05 (+2.44), CBM: 48.07 (-0.42), KITE: 58.66 (+2.68), AMGN: 173.39 (-0.76)

Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 46.05 (+2.44), CBM: 48.07 (-0.42), ANIP: 62.19 (+1.17), ARNA: 1.69 (+0.06)

New Strong Buy Stocks for May 10th
Zacks Equity Research - Zacks Investment Research - Tue May 10, 7:12AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BMA: 73.43 (+1.34), CBM: 48.07 (-0.42), AZPN: 41.23 (-0.26), BBY: 33.40 (+0.54), BEL: 11.35 (+0.09)

Juno (JUNO) Posts Wider Loss in Q1, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:15AM CDT
Even though Juno's (JUNO) Q1 loss was wider-than-expected, investor focus will remain on the company's pipeline progress.
HSKA: 46.05 (+2.44), CBM: 48.07 (-0.42), JUNO: 30.93 (+0.25), CELG: 116.16 (+1.87)

Geron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:18AM CDT
While Geron's (GERN) first quarter loss was in-line with expectations, investor focus remains on imetelstat.
JNJ: 123.97 (-0.88), CBM: 48.07 (-0.42), ANIP: 62.19 (+1.17), GERN: 2.73 (+0.01)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 48.07 (-0.42), OMED: 12.19 (-0.03), LGND: 132.47 (-0.21), ANIK: 47.98 (-1.02)

Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 48.07 (-0.42), OMED: 12.19 (-0.03), ANIP: 62.19 (+1.17), ILMN: 165.90 (-1.02)

Cambrex posts 1Q profit
Automated Insights - Fri Apr 29, 6:40PM CDT
EAST RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Friday reported first-quarter profit of $14.6 million.
CBM: 48.07 (-0.42)

Cambrex Reports First Quarter 2016 Financial Results
GlobeNewswire - Fri Apr 29, 6:00AM CDT
- Sales increased 20% and EBITDA increased 52% vs. prior year quarter -
CBM: 48.07 (-0.42)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading